OncoCyte received final Medicare coverage for DetermaRx, previously the Razor Test, by Palmetto, Piper Sandler analyst Rachel Vatnsdal tells investors in a research note. The final local coverage determination is nearly identical to the draft version and is effective June 14 to allow time for pricing discussions, the analyst adds. Vatnsdal believes reimbursement will be between $3,000-$4,000. Further, Noridian typically follows Palmetto’s lead relatively quickly, says the analyst, who believes the Palmetto final local coverage determination was the key event for DetermaRx. Vatnsdal keeps an Overweight rating on OncoCyte with a $5.40 price target. The stock in morning trading is up 18% to $2.70.